

MOGA 2024 ASM Abstract and Poster Program Guidelines

Call For abstracts opens 19 February

Early bird registration closes 15 June

Call for abstracts closes 30 June

Abstract selection advice 12 July

Introduction

- Submitting authors must comply with these guidelines.
- The Abstract Review Committee reserves the right to reject or return for re-submission with a strict deadline any abstract that does not comply with these guidelines.
- Abstracts are blinded to the members of the Review Committee and are assessed on merit and without any knowledge of authors, prior research, research groups or expertise.

Terms and Conditions

- Abstracts must be submitted by the first or corresponding author and only 2 abstracts per first author can be submitted.
- All first or corresponding authors submitting an abstract must register to attend the ASM. This fee is not refundable if you are unable to attend the meeting. Before submitting your abstract the first or corresponding author must register for the meeting and provide a copy of the receipt of payment as part of the abstract submission process.
- Only abstracts submitted by oncology trainees, clinicians, professionals and researchers can be submitted.
- Abstracts submitted by commercial entities, private research groups, third parties and undergraduate students will not be accepted.
- Previously presented or published (encore) abstracts will not be considered.
- The first or corresponding author will be required to register for the Meeting at the time of submission and present their abstract if it is selected for an oral session. Alternate presenters need to be approved by the Review Committee.
- The Abstract Review Committee has the right of refusal to any abstract submitted at all times.

How to Submit an Abstract

- Authors must submit their abstract using the online system available at MOGA ASM Meeting website.
- Abstracts can be submitted until 11.59 pm on the closing date. No late submissions will be considered.
- Questions-contact MOGA via moga@moga.org.au

Abstract Content

- Abstracts should comprise the following elements, each beginning a new paragraph. Please refer to the sample Abstract provided.

1. Abstract Title

- A brief descriptive title (maximum of 20 words) in initial capital/lower case. Trademarks are not permitted.

2. Authors

- Authors' names should be supplied in the surname-last format and should be in initial capital/lower case.
- Institutional affiliations should be indicated with superscript numbers following each author's name.

3. Affiliation(s)

- This should contain Institution, City, State and Country.

4. Abstract Text

- The text should not exceed 300 words, excluding tables, charts and pictures.
- The Abstract Review Committee may decide to omit a visual at their discretion due to publication requirements.
- Abstracts must be submitted in a Word document, in a text format. Abstracts submitted in a table format will be rejected.
- Abstracts should be written in English and should be carefully proof read.
- The Abstract Review Committee reserves the right to correct abstracts for obvious spelling or grammatical errors without notice.

Abstracts Sections

Abstracts should contain the following sections:

1. **Background:** Aims and objectives of the study, what the study covers, relevant background information and an outline of how the information will be presented.
2. **Methods:** Outline how the study was carried out and how the information was obtained.
3. **Results:** Present the results obtained from data gathering and the study as a whole. Results should be presented clearly, concisely and record only the facts. Relevant tables, graphs or visual evidence should be included in this section. Abstracts reporting quantitative studies should contain the planned accrual target and the actual number of patients recruited, levels of significance and confidence intervals of results.
4. **Conclusion:** State or summarise the main points or findings of the study. This is where the aims of the study are revisited. No new information should be presented in this section.
5. **References and acknowledgements:** A limited number of key literature references may be added at the end of the abstract. The style of the references should follow the style of the Journal e.g. numbered or author/date style. Any references included in a reference list must be cited within the abstract text.
6. **Mention source(s) of funding** and any **other acknowledgements** briefly at the end of the abstract text.
7. **References and acknowledgements are included in the 300 words count.**
8. **Tables/Figures/Illustrations:** One small illustration per abstract is allowed. The illustration must be captioned, relevant to the abstract's scientific content and cited in the text. The illustration must be provided in a high resolution (publication standard) or the Abstract Review Committee may decide to omit the illustration at their discretion.

Oral Presentation and Poster Display

From the accepted abstracts a selection will be scheduled for a face to face oral presentation and poster display or poster display only. Abstracts on completed studies and research outcomes may be given preference in selecting oral presentations, above all, over abstracts which do not report results but indicate that they will be reported at the meeting or contain descriptions of trial methodology.

Presenting Author Registration

If the presenting author cannot present at the time/date for the scheduled face to face oral session an alternate can be considered. Alternate presenters need to be approved by the Review Committee. MOGA does not allow company representatives or staff to present abstracts on behalf of first authors.

No-Show Policy

Should a presenting author be absent without notice during the face-to-face oral session the abstract is scheduled to be presented in, the presentation may be cancelled or presented by the Session Chair.

Trademarks

Trademarks may be used in the abstract text but only in brackets and only once, i.e. the first time the product/service is mentioned. The identity of drugs/technologies described in the abstract should be disclosed by means of a generic name, a brief description or reference to a public source.

Copyright

Submission of an abstract implies the exclusive, unrestricted granting of copyright to MOGA to publish the abstract in the 2024 Online ASM Program, a supplement of the Asia-Pacific Journal of Clinical Oncology, and on the MOGA website. Abstract authors retain full copyright.